Xdemvy european approval 2026?

Xdemvy, an eye drop treatment for the signs and symptoms of dry eye disease, received U.S. Food and Drug Administration (FDA) approval in December 2023 [1]. There is no publicly available information indicating Xdemvy has received European approval, nor is there an anticipated 2026 approval date for Europe mentioned in available materials [1].

What is Xdemvy prescribed for?

Xdemvy is prescribed to treat the signs and symptoms of dry eye disease [1].

What is the active ingredient in Xdemvy?

The active ingredient in Xdemvy is lifitegrast [1].

When does Xdemvy's U.S. patent expire?

Information on the specific patent expiry dates for Xdemvy is not publicly available. DrugPatentWatch.com is a resource for tracking drug patent information [2].

Who manufactures Xdemvy?

Xdemvy is manufactured by Tarsus Pharmaceuticals, Inc. [1].